Cochrane · systematic review · CD004370

Intravenous immunoglobulin for presumed viral myocarditis in children and adults

Robinson, J, Hartling, L, Vandermeer, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Heart2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Intravenous immunoglobulin compared with placebo or no treatment for adults with acute myocarditis

Population: adults with acute myocarditis

CD004370.PUB4 (current) · 3 questions

Outcome	Effect	Evidence	Status / GRADE
Event‐free survival (risk of death, cardiac transplant, or left ventricular assist device) ‐ adults with myocarditis, median Intravenous immunoglobulin vs placebo or no treatment	RR 1.76 [0.48, 6.4]	1 study · 62 participants	Very low Downgraded: risk of bias, imprecision, indirectness
Overall survival (risk of death) ‐ adults with myocarditis, median Intravenous immunoglobulin vs placebo or no treatment	RR 0.91 [0.23, 3.62]	2 studies · 103 participants	Very low Downgraded: risk of bias, imprecision, indirectness
Side effects ‐ mild infusion effects, 12‐month Intravenous immunoglobulin vs placebo or no treatment	RR 20.29 [1.25, 329.93]	1 study · 62 participants	Very low Downgraded: risk of bias, imprecision, indirectness

Intravenous immunoglobulin compared with placebo or no treatment for children with acute myocarditis

Population: children with acute myocarditis

CD004370.PUB4 (current) · 1 question

Outcome	Effect	Evidence	Status / GRADE
Overall survival (risk of death) ‐ children with myocarditis, 6‐month Intravenous immunoglobulin vs placebo or no treatment	RR 0.48 [0.2, 1.15]	1 study · 86 participants	Very low Downgraded: imprecision, indirectness

Comparison

Population: adults or children with acute myocarditis

CD004370.PUB3 · 2 questions

Outcome	Effect	Evidence	Status / GRADE
Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis	OR 0.52	62 participants	Very low
Survival ‐ children with myocarditis and encephalitis	OR 7.39	83 participants	Very low